Shionogi & Co Ltd 2013 Annual Report with Sustainability Disclosures
The report highlights consolidated net sales of ¥282,904 million and record operating income in fiscal 2012. It describes the Group's globalization, including the US launch of Osphena as its first global drug. CSR disclosures cover employee health initiatives, ISO 14001 certification, and a 6.8% reduction in CO2 emissions against the benchmark fiscal year.
Company: Shionogi & Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2013
Type: Annual Report with Sustainability Disclosures
Pages: 78
Back to company
Shionogi & Co Ltd
Annual Report
The report highlights consolidated net sales of ¥282,904 million and record operating income in fiscal 2012. It describes the Group's globalization, including the US launch of Osphena as its first global drug. CSR disclosures cover employee health initiatives, ISO 14001 certification, and a 6.8% reduction in CO2 emissions against the benchmark fiscal year.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2013
Reporting Period
Apr 1, 2012 - Mar 31, 2013
Fiscal Year
2012
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Total Waste
Employees